Cargando…

Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment

BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. The relationship between meningiomas and exogenous sex hormones such as cyproterone acetate (CPA) is well documented, yet the underlying mechanisms remain unknown. Defining the histomolecular status of meningiomas dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Portet, Sylvain, Naoufal, Rania, Tachon, Gaëlle, Simonneau, Adrien, Chalant, Anaïs, Naar, Amir, Milin, Serge, Bataille, Benoit, Karayan-Tapon, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212922/
https://www.ncbi.nlm.nih.gov/pubmed/32642646
http://dx.doi.org/10.1093/noajnl/vdz003
_version_ 1783531698474975232
author Portet, Sylvain
Naoufal, Rania
Tachon, Gaëlle
Simonneau, Adrien
Chalant, Anaïs
Naar, Amir
Milin, Serge
Bataille, Benoit
Karayan-Tapon, Lucie
author_facet Portet, Sylvain
Naoufal, Rania
Tachon, Gaëlle
Simonneau, Adrien
Chalant, Anaïs
Naar, Amir
Milin, Serge
Bataille, Benoit
Karayan-Tapon, Lucie
author_sort Portet, Sylvain
collection PubMed
description BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. The relationship between meningiomas and exogenous sex hormones such as cyproterone acetate (CPA) is well documented, yet the underlying mechanisms remain unknown. Defining the histomolecular status of meningiomas developed on CPA would help us to better understand the oncogenesis of these tumors. METHODS: We identified 30 patients operated for a meningioma after long-term high-dose CPA therapy and with a history of CPA discontinuation before establishing the indication for surgical intervention. We used array-comparative genomic hybridization (to characterize copy number changes in those 30 meningiomas and subsequently performed next-generation sequencing with the National Institute of Cancer (INCa) solid tumor panel, which is a targeted panel of clinically actionable genes. We also examined grade, type, and clinical features. RESULTS: We identified AKT1 mutations or PIK3CA mutations in 33.3% of CPA meningiomas. AKT1 and PIK3CA mutations were mutually exclusive. Enrichment in oncogenic PIK3CA mutations in the CPA cohort was detected. CPA meningiomas showed chromosomal stability and were located mainly in the skull base. Ninety percent of CPA meningiomas were low-grade meningiomas and 63.4% were meningotheliomas. Half of our CPA cohort had microcystic components. CONCLUSION: Our study shows that low-grade meningothelial meningiomas of the skull base are predominant in CPA meningiomas. We identified PIK3CA/AKT1 pathway as a hypothetical actor in onco-pharmacological interaction between meningiomas and CPA. This signaling pathway could be an interesting target for precision medicine trials in meningioma patients who have been subjected to CPA. Our results could invite the scientific community to review the current classification of meningiomas and to evolve toward more specific histomolecular classification.
format Online
Article
Text
id pubmed-7212922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72129222020-07-07 Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment Portet, Sylvain Naoufal, Rania Tachon, Gaëlle Simonneau, Adrien Chalant, Anaïs Naar, Amir Milin, Serge Bataille, Benoit Karayan-Tapon, Lucie Neurooncol Adv Basic and Translational Investigations BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. The relationship between meningiomas and exogenous sex hormones such as cyproterone acetate (CPA) is well documented, yet the underlying mechanisms remain unknown. Defining the histomolecular status of meningiomas developed on CPA would help us to better understand the oncogenesis of these tumors. METHODS: We identified 30 patients operated for a meningioma after long-term high-dose CPA therapy and with a history of CPA discontinuation before establishing the indication for surgical intervention. We used array-comparative genomic hybridization (to characterize copy number changes in those 30 meningiomas and subsequently performed next-generation sequencing with the National Institute of Cancer (INCa) solid tumor panel, which is a targeted panel of clinically actionable genes. We also examined grade, type, and clinical features. RESULTS: We identified AKT1 mutations or PIK3CA mutations in 33.3% of CPA meningiomas. AKT1 and PIK3CA mutations were mutually exclusive. Enrichment in oncogenic PIK3CA mutations in the CPA cohort was detected. CPA meningiomas showed chromosomal stability and were located mainly in the skull base. Ninety percent of CPA meningiomas were low-grade meningiomas and 63.4% were meningotheliomas. Half of our CPA cohort had microcystic components. CONCLUSION: Our study shows that low-grade meningothelial meningiomas of the skull base are predominant in CPA meningiomas. We identified PIK3CA/AKT1 pathway as a hypothetical actor in onco-pharmacological interaction between meningiomas and CPA. This signaling pathway could be an interesting target for precision medicine trials in meningioma patients who have been subjected to CPA. Our results could invite the scientific community to review the current classification of meningiomas and to evolve toward more specific histomolecular classification. Oxford University Press 2019-05-28 /pmc/articles/PMC7212922/ /pubmed/32642646 http://dx.doi.org/10.1093/noajnl/vdz003 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Basic and Translational Investigations
Portet, Sylvain
Naoufal, Rania
Tachon, Gaëlle
Simonneau, Adrien
Chalant, Anaïs
Naar, Amir
Milin, Serge
Bataille, Benoit
Karayan-Tapon, Lucie
Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title_full Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title_fullStr Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title_full_unstemmed Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title_short Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
title_sort histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment
topic Basic and Translational Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212922/
https://www.ncbi.nlm.nih.gov/pubmed/32642646
http://dx.doi.org/10.1093/noajnl/vdz003
work_keys_str_mv AT portetsylvain histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT naoufalrania histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT tachongaelle histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT simonneauadrien histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT chalantanais histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT naaramir histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT milinserge histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT bataillebenoit histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment
AT karayantaponlucie histomolecularcharacterizationofintracranialmeningiomasdevelopedinpatientsexposedtohighdosecyproteroneacetateanantiandrogentreatment